{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:17:24Z","timestamp":1787008644293,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>It remains unclear whether persisting proteinuria in ANCA-associated glomerulonephritis (AAGN) reflects damage from the initial injury or ongoing inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, single-centre study of biopsy-proven AAGN was performed. The study defined the \u2018albuminuria\u2019 group as urine albumin-to-creatinine ratio (ACR) &amp;gt;300\u00a0mg\/g and the \u2018no albuminuria\u2019 group as ACR \u2264300\u00a0mg\/g at 6 months. We sought the clinical and histopathological characteristics of both the initial and subsequent biopsies and long-term kidney outcomes stratified by albuminuria levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred and eighteen patients were included. Within the first 6 months, 28 (13%) died or progressed to end-stage kidney disease (ESKD). Among the remaining 190 patients, 37% had an ACR &amp;gt;300\u00a0mg\/g at 6 months. The albuminuria group more frequently presented with a Berden mixed or crescentic class and had higher glomerular activity on the initial biopsy. They were more often male (OR 2.75; 95% CI 1.15\u20136.54), younger age (OR 0.96; 95% CI 0.93\u20130.99), and had fewer normal glomeruli in the biopsy (OR 0.96; 95% CI 0.93\u20130.99) compared with the group without albuminuria. Over the initial 5-year period, the recovery in eGFR was lower in the albuminuria group (adjusted mean difference in \u0394eGFR \u221212.5\u00a0mL\/min per 1.73\u00a0m2; 95% CI \u221215.8 to \u22129.1). In multivariable analysis, ACR &amp;gt;300\u00a0mg\/g was associated with a higher risk of ESKD, even after adjusting for Berden classification and eGFR at diagnosis (hazard ratio 6.53; 95% CI 1.49\u201328.50).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a well-defined cohort of AAGN, one-third of the patients, primarily younger males with a lower percentage of normal glomeruli, had persisting albuminuria after induction treatment which was associated with worse kidney outcomes independent of Berden class and eGFR at diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfae379","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T15:27:51Z","timestamp":1732289271000},"source":"Crossref","is-referenced-by-count":5,"title":["Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritis"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-3246","authenticated-orcid":false,"given":"Aglaia","family":"Chalkia","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge ,","place":["UK"]},{"name":"Vasculitis & Lupus Clinic, Addenbrooke's Hospital , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge ,","place":["UK"]},{"name":"Vasculitis & Lupus Clinic, Addenbrooke's Hospital , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Willcocks","sequence":"additional","affiliation":[{"name":"Vasculitis & Lupus Clinic, Addenbrooke's Hospital , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge , Cambridge ,","place":["UK"]},{"name":"Vasculitis & Lupus Clinic, Addenbrooke's Hospital , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"2025020409372313300_bib1","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.autrev.2020.102495","article-title":"Clinical associations of renal involvement in ANCA-associated vasculitis","volume":"19","author":"Kronbichler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025020409372313300_bib2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025020409372313300_bib3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome","volume":"58","author":"Trejo","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025020409372313300_bib4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/art.39614","article-title":"Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease","volume":"68","author":"Rhee","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025020409372313300_bib5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025020409372313300_bib6","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/jcm10122682","article-title":"Systematic scoring of tubular injury patterns reveals interplay between distinct tubular and glomerular lesions in ANCA-associated glomerulonephritis","volume":"10","author":"Hakroush","year":"2021","journal-title":"J Clin Med"},{"key":"2025020409372313300_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","article-title":"Rapidly progressive crescentic glomerulonephritis","volume":"63","author":"Jennette","year":"2003","journal-title":"Kidney Int"},{"key":"2025020409372313300_bib8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1046\/j.1523-1755.2003.00840.x","article-title":"Pathophysiology of proteinuria","volume":"63","author":"D'Amico","year":"2003","journal-title":"Kidney Int"},{"key":"2025020409372313300_bib9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020409372313300_bib10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2025020409372313300_bib11","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.kint.2023.02.029","article-title":"Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis","volume":"103","author":"Benichou","year":"2023","journal-title":"Kidney Int"},{"key":"2025020409372313300_bib12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2025020409372313300_bib13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","article-title":"Lack of EULAR\/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis","volume":"79","author":"Moroni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025020409372313300_bib14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020409372313300_bib15","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/ndt\/gfu042","article-title":"Repeat protocol renal biopsy in ANCA-associated renal vasculitis","volume":"29","author":"Hruskova","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2025020409372313300_bib16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1093\/rheumatology\/keab695","article-title":"Utility of interval kidney biopsy in ANCA-associated vasculitis","volume":"61","author":"Chapman","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025020409372313300_bib17","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/jcm10071538","article-title":"Proteinuria indicates decreased normal glomeruli in ANCA-associated glomerulonephritis independent of systemic disease activity","volume":"10","author":"Tampe","year":"2021","journal-title":"J Clin Med"},{"key":"2025020409372313300_bib18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020409372313300_bib19","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0763-7","article-title":"Persistent hematuria in patients with antineutrophil cytoplasmic antibody-associated vasculitis during clinical remission: chronic glomerular lesion or low-grade active renal vasculitis?","volume":"18","author":"Lv","year":"2017","journal-title":"BMC Nephrol"},{"key":"2025020409372313300_bib20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000500352","article-title":"Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis","volume":"49","author":"Vandenbussche","year":"2019","journal-title":"Am J Nephrol"},{"key":"2025020409372313300_bib21","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3899\/jrheum.111608","article-title":"Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy","volume":"39","author":"Geetha","year":"2012","journal-title":"J Rheumatol"},{"key":"2025020409372313300_bib22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10061231","article-title":"Systematic histological scoring reveals more prominent interstitial inflammation in myeloperoxidase-ANCA compared to proteinase 3-ANCA glomerulonephritis","volume":"10","author":"Hakroush","year":"2021","journal-title":"J Clin Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae379\/60800339\/sfae379.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae379\/60800339\/sfae379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/1\/sfae379\/60800339\/sfae379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:37:34Z","timestamp":1738643854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae379\/7907872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae379","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,23]]},"article-number":"sfae379"}}